B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
-7%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.84B
AUM Growth
-$528M
(-16%)
Cap. Flow
-$782M
Cap. Flow
% of AUM
-27.48%
Top 10 Holdings %
Top 10 Hldgs %
40.1%
Holding
81
New
10
Increased
17
Reduced
14
Closed
17
Avg Time Held
1.1
years
Top 10 Avg Time Held
0.7
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$67.5M |
| 2 |
argenx
ARGX
|
+$50.5M |
| 3 |
Nuvalent
NUVL
|
+$46.9M |
| 4 |
Glaukos
GKOS
|
+$44.8M |
| 5 |
Blueprint Medicines
BPMC
|
+$42.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Guardant Health
GH
|
+$65.6M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$43.2M |
| 3 |
Paragon 28, Inc.
FNA
|
+$39.6M |
| 4 |
BioNTech
BNTX
|
+$35.3M |
| 5 |
Repligen
RGEN
|
+$31.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.44% |
| 2 | Miscellaneous | 32.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Skye Bioscience
SKYE
$6.82M
| $1.31M | 0.05% |
103,217
| – | – |
2024 Q4
1 quarter
|
|
52
Trevi Therapeutics
TRVI
$1.74B
| $453K | 0.02% |
+72,083
| New | +$344K |
2025 Q1
0 quarters
|
|
|
AVDL
53
DELISTED
Avadel Pharmaceuticals
AVDL
| – | – |
-4,105,726
| Closed | -$43.2M | – |
|
|
54
BioNTech
BNTX
$22.4B
| – | – |
-309,865
| Closed | -$35.3M | – |
|
55
Bruker
BRKR
$8.49B
| – | – |
-353,200
| Closed | -$20.7M | – |
|
56
Candel Therapeutics
CADL
$699M
| – | – |
-1,600,000
| Closed | -$13.9M | – |
|
57
DELISTED
Exact Sciences
EXAS
| – | – |
-353,000
| Closed | -$19.8M | – |
|
58
4D Molecular Therapeutics
FDMT
$672M
| – | – |
-1,225,448
| Closed | -$6.83M | – |
|
59
Geron
GERN
$771M
| – | – |
-7,006,315
| Closed | -$24.8M | – |
|
60
Immatics
IMTX
$1.04B
| – | – |
-3,503,965
| Closed | -$24.9M | – |
|
61
Jasper Therapeutics
JSPR
$15.6M
| – | – |
-714,658
| Closed | -$15.3M | – |
|
62
Keros Therapeutics
KROS
$221M
| – | – |
-1,894,439
| Closed | -$30M | – |
|
63
Vaxcyte
PCVX
$10.7B
| – | – |
-222,424
| Closed | -$18.2M | – |
|
64
Protagonist Therapeutics
PTGX
$8.88B
| – | – |
-20,109
| Closed | -$776K | – |
|
65
Arcus Biosciences
RCUS
$2.89B
| – | – |
-802,100
| Closed | -$11.9M | – |
|
66
Viridian Therapeutics
VRDN
$2.09B
| – | – |
-34,094
| Closed | -$654K | – |
|
67
CeriBell Inc
CBLL
$1.02B
| – | – |
-210,000
| Closed | -$5.43M | – |
|
|
68
DELISTED
Paragon 28, Inc.
FNA
| – | – |
-3,834,809
| Closed | -$39.6M | – |
|
69
DELISTED
NEVRO CORP.
NVRO
| – | – |
-1,698,768
| Closed | -$6.32M | – |
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q1 2025 Portfolio in Review
As of Q1 2025, Braidwell held 81 positions worth $2.84B, down 16% from $3.37B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Braidwell withdrew a net $782M in Q1 2025, closing 17 positions and reducing 14 holdings. Its most notable exit was Avadel Pharmaceuticals, an estimated $43.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 66% a quarter earlier, followed by Miscellaneous.
Against the trend, Braidwell opened a new position in Danaher worth $63.4M.
- Braidwell's largest Q1 2025 buy was Danaher: 309,339 shares worth $63.4M.
- Braidwell added most to argenx in Q1 2025, an estimated $50.5M increase.
- Braidwell's biggest Q1 2025 reduction was Guardant Health, cutting an estimated $65.6M.
- Braidwell fully exited Avadel Pharmaceuticals in Q1 2025, selling an estimated $43.2M.
- Braidwell's ten largest holdings make up 40% of its $2.84B portfolio in Q1 2025.
- Braidwell opened 10 new positions and closed 17 in Q1 2025.
- Braidwell's portfolio value fell 16% quarter-over-quarter to $2.84B.
Based on Braidwell's 13F filing for Q1 2025, filed 15 May 2025.